3-D Pharmaceuticals begins Phase I

3-Dimensional Pharmaceuticals (Exton, Penn.) began a double-blind, dose rising Phase I study in up to 45 patients of its 3DP 4815 oral anticoagulant thrombin inhibitor to treat arterial and venous thr...